By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

SAGE Therapeutics 

215 First Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-299-8380 Fax: 617-299-8379


SEARCH JOBS

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead program, brexanolone (SAGE-547), is in Phase 3 clinical development for super-refractory status epilepticus, a rare and severe seizure disorder, and for postpartum depression. Sage is developing its next generation modulators, including SAGE-217 and SAGE-718, in various CNS disorders. For more information, please visit www.sagerx.com.


Key Statistics


Email: contact@sagerx.com
Ownership: Public

Web Site: SAGE Therapeutics
Employees:
Symbol: SAGE
 



Industry
Biotechnology






Company News
Does SAGE Therapeutics (SAGE)' Failure Predict Its Future Results? 9/13/2017 5:55:13 AM
SAGE Therapeutics (SAGE) Crashes Hard as Lead Epilepsy Drug Flunks Phase III Test 9/12/2017 5:37:21 AM
SAGE Therapeutics (SAGE) Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 9/7/2017 6:49:55 AM
SAGE Therapeutics (SAGE) Announces Second Quarter 2017 Financial Results And Provides Pipeline Update 8/4/2017 8:08:46 AM
SAGE Therapeutics (SAGE) To Report Second Quarter 2017 Financial Results On Thursday, August 3, 2017 7/21/2017 7:49:11 AM
SAGE Therapeutics (SAGE) Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) 7/11/2017 7:28:55 AM
SAGE Therapeutics (SAGE) Announces The Lancet Publishes Positive Phase II Brexanolone (SAGE-547) Clinical Data In Severe Postpartum Depression 6/13/2017 7:05:54 AM
SAGE Therapeutics (SAGE) Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 6/5/2017 7:46:37 AM
SAGE Therapeutics (SAGE) Receives Fast Track Designation For SAGE-217 For The Treatment Of Major Depressive Disorder 5/18/2017 6:23:16 AM
SAGE Therapeutics (SAGE) Announces First Quarter 2017 Financial Results And Provides Pipeline Update 5/10/2017 7:24:01 AM
12345678910...
//-->